Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 64

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 64
---
 shall have received payment, by wire transfer of immediately available funds, in the full amount of the
purchase price for the Securities being purchased by each Investor at the applicable Closing.

7. .

7.1 . The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall
terminate as follows:

(a) Upon the mutual written consent of the Company and the Investors that agreed to purchase a majority of the
Securities prior to the Closing;

(b) By the Company if any of the conditions set forth in shall
have become incapable of fulfillment, and shall not have been waived by the Company; or

(c) By an Investor (with respect to itself only)
if any of the conditions set forth in shall have become incapable of fulfillment, and shall not have been waived by such Investor;

provided, however, that, in the case of clauses (b) and (c) above, the party seeking to terminate its obligation to effect the Closing
shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its
obligation to effect the Applicable Closing.

7.2 . In the event of termination by the Company or the Investor of its
obligations to effect the Closing pursuant to , written notice thereof shall be given to the other party. Nothing in this shall be deemed to release any party from any
liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction Agreements.

20

8. .

8.1 . Except as set forth in , neither the Company nor any Investor
shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld). Notwithstanding the
foregoing, and subject to compliance with , nothing in this shall prevent any party from making any public announcement it considers necessary in order to satisfy its
obligations under the law, including applicable securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall allow the Investors reasonable time to comment on such release or
announcement in advance of such issuance, and the Company will consider in good faith any Investor comments.